The Quantellect read.As of Nov 19, 2026, 4 active firms cover Sanofi ADR: 0 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 0 over recent months.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Neutral
Strong Buy00%
Buy00%
Neutral4100%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
—
Average target across 0 active firms as of Nov 19, 2026 vs $47.11 current
Highest Target—
Average Target—
Lowest Target—
Detailed analyst forecasts for SNY
Showing 1–3 of 3 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 0 of 4 active firms rate SNY a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SNY EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 0 analysts
Next period, 0 analysts expect Sanofi ADR to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $5.06, growing to $5.43 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 0 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $48.4B, rising to $51.7B next year.
Top analysts covering Sanofi ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SNY.
#1
Seamus Fernandez
Guggenheim
Neutral
No targeton SNY
Coverage
—
+ Follow
#2
RV
Richard Vosser
JP Morgan
Neutral
No targeton SNY
Coverage
—
+ Follow
#3
JQ
James Quigley
Goldman Sachs
Neutral
$60.00+27.4% to target
Coverage
—
+ Follow
#4
PV
Peter Verdult
Exane BNP Paribas
Neutral
$50.00+6.1% to target
Coverage
—
+ Follow
#5
MW
Matthew Weston
UBS
Neutral
No targeton SNY
Coverage
—
+ Follow
SNY stock forecast FAQ
Is SNY stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 4 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover SNY?+
4 active firms have a recognized rating on Sanofi ADR as of Nov 19, 2026.
Who is the most accurate analyst covering SNY?+
Among analysts who currently cover SNY, Seamus Fernandez of Guggenheim has the strongest overall Quantellect track record. Their current call is Neutral.
What is Sanofi ADR's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 0 analysts. Full-year EPS is projected at $5.06, rising to $5.43 the following year.
How much revenue is Sanofi ADR expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $48.4B, growing to $51.7B next year.
Have analysts been upgrading or downgrading SNY lately?+
As of Nov 19, 2026, 0 of 4 active firms rate SNY a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SNY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.